Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05523297 · ClinicalTrials.gov registry record · Phase 3

Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

A Phase 3 study, sponsored by Octapharma.

Completed
Registry status
Phase 3
Development phase
420
Enrollment target

NCT05523297 is a Phase 3 study that has completed, run by Octapharma. The registered enrollment target is 420 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05523297, a Phase 3 study, has completed, sponsored by Octapharma.

COMPLETED
Registry status
Phase 3
Development phase
420 participants
Enrollment target

Study Summary

This is a multicenter, active-control randomized, prospective, Phase 3 study in adult cardiac surgery patients. 420 patients were randomized at 12 hospitals.

Interventions

  • DRUG Octaplex
  • DRUG Frozen Plasma Product, Human

Trial Details

FieldValue
Enrollment Target 420 participants
Start Date 2022-11-30
Est. Completion 2024-06-27
Phase Phase 3

Sponsor

Octapharma

43 total trials

What the Registry Record Tells You About NCT05523297

The ClinicalTrials.gov registry entry for NCT05523297 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Octaplex is the first listed.

NCT05523297 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05523297 about?

NCT05523297 is a clinical study titled "Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery". This is a multicenter, active-control randomized, prospective, Phase 3 study in adult cardiac surgery patients. 420 patients were randomized at 12 hospitals.

What is the current status of trial NCT05523297?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 420 participants. The study started on 2022-11-30. Estimated completion is 2024-06-27.

What interventions are being tested in trial NCT05523297?

The interventions under investigation include: Octaplex (DRUG), Frozen Plasma Product, Human (DRUG).

Who is sponsoring clinical trial NCT05523297?

This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.